Envestnet Asset Management
WINT

Envestnet Asset Management’s Windtree Therapeutics WINT Stock Holding History

Envestnet Asset Management’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5
Closed -$36.1K – 4124
2022
Q4 		$36.1K Buy
5
+3
+150% +$26.7K ﹤0.01% 3896
2022
Q3 		$32K Buy
+2
New +$35.7K ﹤0.01% 3846
2022
Q2 		– Hold
0
– – – 3911
2022
Q1 		– Hold
0
– – – 3920
2021
Q3 		– Sell
-1
Closed -$88K – 3771
2021
Q2 		$88K Hold
1
– – ﹤0.01% 3574
2021
Q1 		$89K Buy
+1
New +$216K ﹤0.01% 3427

Other funds holding WINT

TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
GI
Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Envestnet Asset Management's WINT Position: Q1 2023 in Review

Envestnet Asset Management sold out of Windtree Therapeutics (WINT) in Q1 2023, closing a stake of 5 shares — an estimated $36.1K sold.

Envestnet Asset Management first reported a position in WINT in Q1 2021 and held it in 4 quarters. The position peaked at $89K in Q1 2021. 2 funds tracked by Wall St. Rank hold WINT as of Q1 2023.

  • Envestnet Asset Management reported no remaining Windtree Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Envestnet Asset Management sold 5 Windtree Therapeutics shares in Q1 2023, an estimated $36.1K.
  • Envestnet Asset Management first reported a position in Windtree Therapeutics in Q1 2021 and held it in 4 quarters.
  • Envestnet Asset Management's Windtree Therapeutics position peaked at $89K in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2023.

Based on Envestnet Asset Management's 13F filing for Q1 2023, filed 11 May 2023.